10.25384/SAGE.C.6301773.V1
Han-Qing Liu
Han-Qing
Liu
Wei-Xin Li
Wei-Xin
Li
Ya-Wen An
Ya-Wen
An
Tao Wu
Tao
Wu
Guang-Yu Jiang
Guang-Yu
Jiang
Yu Dong
Yu
Dong
Wei-Xin Chen
Wei-Xin
Chen
Jian-Chun Wang
Jian-Chun
Wang
Cheng Wang
Cheng
Wang
Shuo Song
Shuo
Song
Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations
<div><p><b>Background:</b> The gene mutation of isocitrate dehydrogenase-1 (IDH1) is commonly found in LGG and some GBM patients and usually carries tumor protein 53 (TP53) mutations. However, the underlying mechanisms on both mutations of glioma patients in IDH1 and TP53 are still unclear. <b>Aim:</b> To find the potential target markers in GBM and LGG patients with IDH1 and TP53 mutation.<b>Method:</b> A total of 1122 glioma patients from The Cancer Genome Atlas were enrolled and divided as wild-type (without IDH1 and TP53 mutations) or both mutant (both IDH1 and TP53 mutations). The data of clinicopathological characteristics, mRNA, mutations, and copy number alteration were analyzed. <b>Results:</b> IDH1 and TP53 mutations, not gene expression, affect the survival probability of GBM and LGG patients, which might be related to neuron function, immune function, tumor invasion, and metastasis. The effects of the selected gene (EMILIN3, SAA1, VSTM2A, HAMP, IFT80, and CHIC2) on glioma patients could be regulated by IDH1 and TP53 mutations and had a higher survival possibility in these patients. <b>Conclusions:</b> The selected genes in GBM and LGG patients with IDH1 and TP53 mutations could be a potential prognosis marker in the future.</p></div>
Medicine
Infectious Diseases
Aged Health Care
Paediatrics
Pharmacology and Pharmaceutical Sciences not elsewhere classified
Respiratory Diseases
Veterinary Medicine
Cell Biology
Biochemistry
Biological Sciences not elsewhere classified
Pharmacology and Pharmaceutical Sciences not elsewhere classified
SAGE Journals
2022
2022-11-16
2022-11-16
Collection
10.25384/SAGE.c.6301773
CC BY 4.0